Literature DB >> 1316140

In vitro toxicity of 3'-azido-3'-deoxythymidine, carbovir and 2',3'-didehydro-2',3'-dideoxythymidine to human and murine haematopoietic progenitor cells.

D L Du1, D A Volpe, C K Grieshaber, M J Murphy.   

Abstract

The myelotoxicities of three antiretroviral agents, 3'-azido-3'-deoxythymidine (AZT), carbovir (CBV) and 2',3'-didehydro-2',3'-dideoxythymidine (d4T), were evaluated in vitro with normal human and murine haematopoietic progenitor cells. These studies demonstrated that continuous AZT exposure was more inhibitory to human and murine colony formation than 1 h exposure, with murine and human progenitors similarly inhibited by continuous AZT exposure. These in vitro results on AZT's myelotoxicity correlate with both human and murine in vivo studies. CBV was only moderately toxic to human and murine cells following either 1 h or continuous exposure, with human and murine progenitors similarly suppressed by continuous CBV exposure. 1 h d4T exposure was less toxic to both human and murine marrow cells than continuous exposure and both species were equivalently inhibited when continuously exposed to d4T. In general, CBV was the least toxic agent to human and murine haematopoietic cells and AZT the most toxic. The study establishes CBV and d4T as less myelotoxic agents to human and murine haematopoietic progenitor cells in vitro than AZT which therefore could be considered as alternatives to AZT for the treatment of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316140     DOI: 10.1111/j.1365-2141.1992.tb04555.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

Authors:  S M Daluge; S S Good; M B Faletto; W H Miller; M H St Clair; L R Boone; M Tisdale; N R Parry; J E Reardon; R E Dornsife; D R Averett; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  Prenatal and postpartum pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina).

Authors:  A Odinecs; C Pereira; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Zidovudine does not affect transplacental transfer or systemic clearance of stavudine (2',3'-didehydro-3'-deoxythymidine) in the pigtailed macaque (Macaca nemestrina).

Authors:  A Odinecs; C Nosbisch; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism.

Authors:  W B Parker; S C Shaddix; B J Bowdon; L M Rose; R Vince; W M Shannon; L L Bennett
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.

Authors:  Roger G Ptak; Brian G Gentry; Tracy L Hartman; Karen M Watson; M Clayton Osterling; Robert W Buckheit; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

6.  Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity.

Authors:  M Barry; J L Howe; D J Back; A M Swart; A M Breckenridge; I V Weller; N Beeching; F Nye
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 7.  HIV RNA suppression and immune restoration: can we do better?

Authors:  Marilia Rita Pinzone; Michelino Di Rosa; Bruno Cacopardo; Giuseppe Nunnari
Journal:  Clin Dev Immunol       Date:  2012-03-25

8.  Pattern expression of glycan residues in AZT-treated K562 cells analyzed by lectin cytochemistry.

Authors:  Anna Rita Lizzi; Anna Maria D'Alessandro; Argante Bozzi; Benedetta Cinque; Arduino Oratore; Gabriele D'Andrea
Journal:  Mol Cell Biochem       Date:  2007-04-12       Impact factor: 3.842

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.